.Biogen has handed back liberties to a very early Alzheimer’s disease program to Denali Therapies, going out of a big hole in the biotech’s partnership
Read moreBiogen containers SAGE-324 cooperation after crucial trembling fail
.Biogen has administered the last ceremonies to its partnership with Sage Therapies on SAGE-324, junking the partnership in the consequences of a failed study that
Read moreBiogen, UCB document phase 3 lupus gain after failing earlier trial
.Biogen and UCB’s bank on developing into period 3 on the back of a failed research seeks to have repaid, with the companions reporting favorable
Read moreBiogen CMO Maha Radhakrishnan joins Sofinnova– Chutes & Ladders
.Invite to this week’s Chutes & Ladders, our summary of substantial leadership hirings, firings and retirings all over the business. Please deliver the recommendation– or
Read moreBioMarin standstills preclinical gene therapy for heart disease
.After BioMarin carried out a springtime clean of its pipe in April, the provider has made a decision that it also requires to offload a
Read moreBioMarin goes Backpacking, striking RNA handle biotech
.BioMarin is incorporating combustion to the R&D fire, blowing a suit with CAMP4 Therapies for civil liberties to select 2 aim ats determined by the
Read moreBioMarin builds director group along with biotech veterinarians– Chutes & Ladders
.Invite to today’s Chutes & Ladders, our summary of significant leadership hirings, firings and also retirings around the market. Please deliver the recommendation– or even
Read moreBioAge introduces $198M from IPO as weight problems biotech participates in Nasdaq
.BioAge Labs is actually introducing practically $200 million by means of its Nasdaq IPO today, with the profits earmarked for taking its lead excessive weight
Read moreBioAge eyes $180M from IPO, personal positioning for excessive weight tests
.BioAge Labs is looking at all around $180 thousand in initial proceeds coming from an IPO and a private positioning, funds the metabolic-focused biotech will
Read moreBig pharma, biotech ‘won’t automatically be cooperative’ in AI: S&P
.Big Pharma is putting in heavily in AI to lower development timelines and also foster development. However instead of enhancing potential relationships along with the
Read more